Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctiontranscription corepressor activity

BCOR CIR1 MED1

5.04e-0522973GO:0003714
GeneOntologyMolecularFunctiontranscription coactivator binding

CCNT2 MED1

1.49e-045472GO:0001223
GeneOntologyMolecularFunctionmolecular adaptor activity

BCOR CIR1 MLLT3 MED1

6.27e-04135674GO:0060090
GeneOntologyMolecularFunctiontranscription coregulator activity

BCOR CIR1 MED1

7.13e-0456273GO:0003712
GeneOntologyMolecularFunctiontranscription coregulator binding

CCNT2 MED1

1.00e-0314072GO:0001221
GeneOntologyMolecularFunctionhistone deacetylase binding

BCOR CIR1

1.10e-0314772GO:0042826
GeneOntologyMolecularFunctionchromatin binding

CCNT2 MLLT3 MED1

1.58e-0373973GO:0003682
GeneOntologyMolecularFunctiontranscription factor binding

BCOR CCNT2 MED1

1.67e-0375373GO:0008134
GeneOntologyMolecularFunctionprotein-macromolecule adaptor activity

BCOR CIR1 MED1

5.74e-03116073GO:0030674
GeneOntologyMolecularFunctionubiquitin-protein transferase activity

BCOR MED1

1.09e-0247372GO:0004842
GeneOntologyMolecularFunctionubiquitin-like protein transferase activity

BCOR MED1

1.27e-0251272GO:0019787
GeneOntologyMolecularFunctionaminoacyltransferase activity

BCOR MED1

1.36e-0253272GO:0016755
GeneOntologyMolecularFunctionDNA-binding transcription factor binding

BCOR MED1

1.62e-0258272GO:0140297
GeneOntologyBiologicalProcesshematopoietic stem cell differentiation

MLLT3 MED1

1.06e-044772GO:0060218
GeneOntologyBiologicalProcesspositive regulation of transcription elongation by RNA polymerase II

CCNT2 MED1

1.40e-045472GO:0032968
GeneOntologyBiologicalProcesspositive regulation of DNA-templated transcription, elongation

CCNT2 MED1

1.85e-046272GO:0032786
GeneOntologyBiologicalProcessregulation of transcription elongation by RNA polymerase II

CCNT2 MED1

4.16e-049372GO:0034243
GeneOntologyBiologicalProcessregulation of DNA-templated transcription elongation

CCNT2 MED1

5.30e-0410572GO:0032784
GeneOntologyBiologicalProcessin utero embryonic development

BCOR CIR1 MED1

7.70e-0459673GO:0001701
GeneOntologyBiologicalProcesstranscription elongation by RNA polymerase II

CCNT2 MED1

7.74e-0412772GO:0006368
GeneOntologyBiologicalProcessDNA-templated transcription elongation

CCNT2 MED1

9.93e-0414472GO:0006354
GeneOntologyBiologicalProcesshematopoietic progenitor cell differentiation

MLLT3 MED1

1.85e-0319772GO:0002244
GeneOntologyBiologicalProcesschordate embryonic development

BCOR CIR1 MED1

2.59e-0390673GO:0043009
GeneOntologyBiologicalProcessembryo development ending in birth or egg hatching

BCOR CIR1 MED1

2.78e-0392973GO:0009792
GeneOntologyBiologicalProcessprotein-DNA complex organization

BCOR MLLT3 MED1

3.42e-0399973GO:0071824
GeneOntologyBiologicalProcessnegative regulation of transcription by RNA polymerase II

BCOR CIR1 MED1

3.98e-03105373GO:0000122
GeneOntologyBiologicalProcessstem cell differentiation

MLLT3 MED1

4.39e-0330672GO:0048863
GeneOntologyCellularComponenttranscription elongation factor complex

CCNT2 MLLT3

1.47e-045672GO:0008023
GeneOntologyCellularComponentnuclear protein-containing complex

BCOR CCNT2 MLLT3 MED1

5.58e-04137774GO:0140513
GeneOntologyCellularComponenttransferase complex

BCOR CCNT2 MED1

2.97e-0396373GO:1990234
GeneOntologyCellularComponentubiquitin ligase complex

BCOR MED1

5.61e-0335272GO:0000151
MousePhenodecreased presacral vertebrae number

CIR1 MLLT3

1.01e-044552MP:0000461
MousePhenodecreased rib number

CIR1 MLLT3

1.62e-045752MP:0003345
MousePhenodecreased vertebrae number

CIR1 MLLT3

1.98e-046352MP:0004645
MousePhenoabnormal vertebrae number

CIR1 MLLT3

3.04e-047852MP:0004643
MousePhenoabnormal rib joint morphology

CIR1 MLLT3

3.70e-048652MP:0004625
MousePhenomicrocephaly

BCOR MED1

4.70e-049752MP:0000433
MousePhenoabnormal placental labyrinth vasculature morphology

CIR1 MED1

4.90e-049952MP:0008803
MousePhenoabnormal cervical vertebrae morphology

CIR1 MLLT3

7.19e-0412052MP:0003048
MousePhenoabnormal synovial joint morphology

CIR1 MLLT3

7.67e-0412452MP:0030804
MousePhenoabnormal head size

BCOR MED1

9.76e-0414052MP:0011496
MousePhenovertebral fusion

CIR1 MLLT3

1.32e-0316352MP:0004609
MousePhenofused joints

CIR1 MLLT3

1.44e-0317052MP:0003189
MousePhenoabnormal cardiovascular development

BCOR CIR1 MED1

1.72e-0380253MP:0002925
MousePhenoabnormal placenta vasculature

CIR1 MED1

1.83e-0319252MP:0003231
MousePhenoabnormal placenta labyrinth morphology

CIR1 MED1

1.86e-0319452MP:0001716
MousePhenoabnormal forebrain development

BCOR MED1

2.50e-0322552MP:0003232
MousePhenoabnormal presacral vertebrae morphology

CIR1 MLLT3

2.50e-0322552MP:0000459
MousePhenoabnormal gland development

CIR1 MED1

2.68e-0323352MP:0020973
MousePhenoabnormal rib morphology

CIR1 MLLT3

3.25e-0325752MP:0000150
PathwayKEGG_MEDICUS_VARIANT_MLL_AF4_FUSION_TO_TRANSCRIPTIONAL_ACTIVATION

CCNT2 MLLT3

4.88e-052662M47439
PathwayREACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX

CCNT2 MLLT3

2.47e-045862M805
PathwayREACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX

CCNT2 MLLT3

2.56e-045962MM14504
PathwayREACTOME_RNA_POLYMERASE_II_PRE_TRANSCRIPTION_EVENTS

CCNT2 MLLT3

4.82e-048162M865
PathwayREACTOME_RNA_POLYMERASE_II_PRE_TRANSCRIPTION_EVENTS

CCNT2 MLLT3

5.06e-048362MM15314
PathwayREACTOME_GENE_EXPRESSION_TRANSCRIPTION

CCNT2 MLLT3 MED1

6.43e-03102263MM15436
Pubmed

MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

BCOR CCNT2 MLLT3

1.82e-09147320854876
Pubmed

BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC Activity.

BCOR MLLT3

3.47e-0827232954361
Pubmed

The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor.

BCOR MLLT3

3.47e-0827212776190
Pubmed

Human mediator subunit MED26 functions as a docking site for transcription elongation factors.

CCNT2 MLLT3 MED1

3.09e-07737321729782
Pubmed

Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding.

BCOR MLLT3

3.47e-0757223260655
Pubmed

BCoR, a novel corepressor involved in BCL-6 repression.

BCOR MLLT3

1.56e-06107210898795
Pubmed

Characterization of the DOT1L network: implications of diverse roles for DOT1L.

BCOR MLLT3

2.84e-05417220431927
Pubmed

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.

BCOR MLLT3

3.27e-05447227505670
Pubmed

Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping.

BCOR MED1

1.04e-04787228611094
Pubmed

Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.

BCOR MED1

1.17e-04837228794006
InteractionMLLT3 interactions

BCOR CCNT2 MLLT3

2.50e-068573int:MLLT3
InteractionMED26 interactions

CCNT2 MLLT3 MED1

5.01e-0610773int:MED26
InteractionMLLT1 interactions

BCOR CCNT2 MLLT3

7.63e-0612373int:MLLT1
InteractionELL3 interactions

CCNT2 MLLT3

3.35e-052672int:ELL3
InteractionCCNT1 interactions

CCNT2 MLLT3 MED1

4.65e-0522573int:CCNT1
InteractionELL2 interactions

CCNT2 MLLT3

5.43e-053372int:ELL2
InteractionCCNT2 interactions

CCNT2 MLLT3

1.94e-046272int:CCNT2
InteractionAPOA2 interactions

CIR1 MED1

5.98e-0410972int:APOA2
InteractionAFF4 interactions

CCNT2 MLLT3

6.65e-0411572int:AFF4
CytobandEnsembl 112 genes in cytogenetic band chrXp11

ITIH6 BCOR

1.37e-0337772chrXp11
CoexpressionGSE16385_IFNG_TNF_VS_UNSTIM_MACROPHAGE_ROSIGLITAZONE_TREATED_DN

BCOR CCNT2 MED1

1.50e-0520073M8032
ToppCellrenal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_ascending_limb_epithelial_cell-Ascending_Thin_Limb_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ITIH6 MUCL3

1.75e-041317272340ea139a6616a466b417949e273f473fba993
ToppCellsaliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage-macrophage,_alveolar-Macro_c2-CCL3L1|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)

BCOR CCNT2

2.71e-0416372130c84bca3f72ab7d1a4fee2990c3d01600318ed
ToppCelldroplet-Marrow-nan-24m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CIR1 MLLT3

2.84e-041677254576e9863403d0d5e3046e61db1ad695d88fee4
ToppCelldroplet-Spleen-SPLEEN-30m-Hematologic-erythroblast|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CIR1 MLLT3

3.05e-0417372a8fb8db6061fa4d8d56a7b45004ecbd344501573
ToppCelldroplet-Marrow-BM_(NON-STC)-30m-Lymphocytic-immature_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CIR1 MLLT3

3.08e-041747281ab196e36cac2a7974d6e3fe457efffddfd03bb
ToppCellNon-neuronal-Postmitotic-Red_blood_cells-Low_Quality-14|World / Primary Cells by Cluster

BCOR MLLT3

3.67e-0419072feadd834d843f952aa7ced93899fd1f0868743df
ToppCellNon-neuronal-Postmitotic-Red_blood_cells|World / Primary Cells by Cluster

BCOR MLLT3

3.67e-0419072f0b82334375749d917e440c493f10340c52ea13c
ToppCellNon-neuronal-Postmitotic-Red_blood_cells-Low_Quality|World / Primary Cells by Cluster

BCOR MLLT3

3.67e-041907231cf1367db5c04242621f7c98a10d094bc519e31
ToppCellTCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6|TCGA-Prostate / Sample_Type by Project: Shred V9

BCOR MED1

3.79e-0419372abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
DrugPHA-00846566E [724718-26-7]; Up 200; 10uM; PC3; HT_HG-U133A

CCNT2 MLLT3 MED1

2.08e-05194737086_UP
DrugFenofibrate [49562-28-9]; Up 200; 11uM; MCF7; HT_HG-U133A

BCOR CCNT2 MED1

2.14e-05196737432_UP
DrugAC1L2E0P

CCNT2 MLLT3 MED1

8.16e-0530773CID000019390
DrugProscillaridin A [466-06-8]; Up 200; 7.6uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.01e-03160724404_UP
DrugDigitoxigenin [143-62-4]; Up 200; 10.6uM; HL60; HT_HG-U133A

CCNT2 MED1

1.03e-03162721339_UP
DrugDigitoxigenin [143-62-4]; Up 200; 10.6uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.10e-03167724801_UP
DrugLY 294002; Up 200; 10uM; PC3; HT_HG-U133A

CIR1 CCNT2

1.29e-03181721236_UP
Drugscriptaid; Down 200; 10uM; PC3; HT_HG-U133A

CCNT2 MED1

1.30e-03182726896_DN
Drug17-AAG; Up 200; 1uM; PC3; HT_HG-U133A

CCNT2 MED1

1.31e-03183721206_UP
DrugMitoxantrone dihydrochloride [70476-82-3]; Down 200; 7.8uM; MCF7; HT_HG-U133A

BCOR CCNT2

1.31e-03183723232_DN
DrugProgesterone [57-83-0]; Down 200; 12.8uM; HL60; HT_HG-U133A

CCNT2 MLLT3

1.36e-03186722426_DN
DrugMycophenolic acid [24280-93-1]; Down 200; 12.4uM; MCF7; HT_HG-U133A

BCOR CCNT2

1.43e-03191722857_DN
DrugNitrarine dihydrochloride [20069-05-0]; Up 200; 10.6uM; PC3; HT_HG-U133A

CIR1 CCNT2

1.44e-03192727382_UP
DrugRapamycin; Up 200; 0.1uM; PC3; HT_HG-U133A

BCOR CCNT2

1.44e-03192721207_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A

CCNT2 MLLT3

1.44e-03192721284_UP
DrugSalsolinol hydrobromide [38221-21-5]; Down 200; 15.4uM; MCF7; HT_HG-U133A

CIR1 CCNT2

1.44e-03192724816_DN
Drugionomycin calcium salt; Down 200; 2uM; MCF7; HT_HG-U133A_EA

CIR1 CCNT2

1.46e-0319372979_DN
DrugThioguanosine [85-31-4]; Up 200; 12.6uM; HL60; HT_HG-U133A

CCNT2 MLLT3

1.47e-03194721264_UP
DrugSertaconazole nitrate [99592-39-9]; Down 200; 8uM; MCF7; HT_HG-U133A

MLLT3 MED1

1.47e-03194726811_DN
Drugpioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A

MLLT3 MED1

1.47e-03194726893_DN
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A

CIR1 CCNT2

1.47e-03194721632_UP
Drug2-propylpentanoic acid; Down 200; 50uM; HL60; HT_HG-U133A

CCNT2 MED1

1.49e-03195721163_DN
DrugDrofenine hydrochloride [548-66-3]; Up 200; 11.4uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.49e-03195723455_UP
DrugFendiline hydrochloride [13636-18-5]; Up 200; 11.4uM; HL60; HG-U133A

CCNT2 MLLT3

1.49e-03195721573_UP
DrugPrednisone [53-03-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.49e-03195721478_DN
DrugNS-398; Down 200; 10uM; PC3; HT_HG-U133A

MLLT3 MED1

1.49e-03195726892_DN
Drugradicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A

MLLT3 MED1

1.49e-03195726979_DN
DrugTerconazole [67915-31-5]; Down 200; 7.6uM; MCF7; HT_HG-U133A

BCOR MLLT3

1.50e-03196722844_DN
DrugClorsulon [60200-06-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A

CIR1 CCNT2

1.50e-03196727025_UP
DrugLY 294002; Down 200; 0.1uM; MCF7; HT_HG-U133A

MLLT3 MED1

1.50e-03196726976_DN
DrugPyrimethamine [58-14-0]; Down 200; 16uM; MCF7; HT_HG-U133A

CCNT2 MLLT3

1.50e-03196721474_DN
DrugFluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A

MLLT3 MED1

1.50e-03196725290_DN
DrugEucatropine hydrochloride [536-93-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A

CCNT2 MLLT3

1.50e-03196723416_DN
DrugCetirizine dihydrochloride [83881-52-1]; Down 200; 8.6uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.50e-03196722829_DN
DrugSulfacetamide sodic hydrate [6209-17-2]; Down 200; 15.8uM; MCF7; HT_HG-U133A

BCOR CCNT2

1.50e-03196721695_DN
DrugNicardipine hydrochloride [54527-84-3]; Down 200; 7.8uM; MCF7; HT_HG-U133A

CIR1 CCNT2

1.52e-03197725397_DN
Drugtroglitazone; Down 200; 10uM; MCF7; HT_HG-U133A_EA

BCOR CCNT2

1.52e-03197721012_DN
DrugEthamsylate [2624-44-4]; Down 200; 15.2uM; HL60; HT_HG-U133A

BCOR MED1

1.52e-03197722915_DN
DrugBromocryptine mesylate [22260-51-1]; Up 200; 5.4uM; PC3; HG-U133A

CCNT2 MED1

1.52e-03197721925_UP
DrugMesoridazine besylate [32672-69-8]; Down 200; 7.4uM; HL60; HG-U133A

CIR1 CCNT2

1.52e-03197721725_DN
Drug1,5-Isoquinolinediol; Up 200; 100uM; HL60; HG-U133A

CCNT2 MLLT3

1.52e-0319772543_UP
DrugMorantel tartrate [26155-31-7]; Up 200; 10.8uM; MCF7; HT_HG-U133A

MLLT3 MED1

1.52e-03197721676_UP
DrugCefoxitin sodium salt [33564-30-6]; Up 200; 8.8uM; PC3; HT_HG-U133A

CCNT2 MLLT3

1.52e-03197727148_UP
DrugMinoxidil [38304-91-5]; Down 200; 19.2uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.52e-03197721496_DN
DrugPridinol methanesulfonate salt [6856-31-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A

CIR1 MLLT3

1.52e-03197723456_DN
DrugCarcinine [56897-53-1]; Up 200; 22uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.52e-03197723242_UP
DrugPergolide mesylate [66104-23-2]; Down 200; 9.8uM; MCF7; HT_HG-U133A

CCNT2 MLLT3

1.52e-03197727434_DN
DrugBuspirone hydrochloride [33386-08-2]; Up 200; 9.4uM; HL60; HT_HG-U133A

CCNT2 MLLT3

1.52e-03197721282_UP
DrugRibavirin [36791-04-5]; Down 200; 16.4uM; MCF7; HT_HG-U133A

BCOR CIR1

1.52e-03197726018_DN
DrugNabumetone [42924-53-8]; Down 200; 17.6uM; MCF7; HT_HG-U133A

CIR1 CCNT2

1.52e-03197726487_DN
DrugPyridoxine hydrochloride [58-56-0]; Down 200; 19.4uM; MCF7; HT_HG-U133A

CIR1 MED1

1.52e-03197727171_DN
DrugCefuroxime sodium salt [56238-63-2]; Up 200; 9uM; MCF7; HT_HG-U133A

CIR1 MED1

1.52e-03197726261_UP
DrugDioxybenzone [131-53-3]; Down 200; 16.4uM; PC3; HT_HG-U133A

BCOR CCNT2

1.52e-03197724638_DN
DrugVincamine [1617-90-9]; Down 200; 11.2uM; PC3; HT_HG-U133A

CCNT2 MLLT3

1.52e-03197723784_DN
DrugPraziquantel [55268-74-1]; Down 200; 12.8uM; HL60; HG-U133A

BCOR CCNT2

1.54e-03198721572_DN
DrugGlycopyrrolate [596-51-0]; Up 200; 10uM; PC3; HT_HG-U133A

CCNT2 MLLT3

1.54e-03198727386_UP
DrugHydrocotarnine hydrobromide [5985-00-2]; Down 200; 13.2uM; MCF7; HT_HG-U133A

BCOR MLLT3

1.54e-03198726827_DN
DrugTridihexethyl chloride; Down 200; 11.4uM; MCF7; HT_HG-U133A

CIR1 MLLT3

1.54e-03198725486_DN
DrugFamotidine [76824-35-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.54e-03198721529_UP
DrugCeftazidime pentahydrate [78439-06-2]; Up 200; 6.2uM; MCF7; HT_HG-U133A

CIR1 CCNT2

1.54e-03198725473_UP
DrugAcetohexamide [968-81-0]; Down 200; 12.4uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.54e-03198727482_DN
DrugAmprolium hydrochloride [137-88-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.54e-03198721479_DN
DrugFuraltadone hydrochloride [3759-92-0]; Down 200; 11uM; PC3; HT_HG-U133A

CCNT2 MLLT3

1.54e-03198723756_DN
DrugPyrilamine maleate [59-33-6]; Down 200; 10uM; PC3; HT_HG-U133A

CIR1 CCNT2

1.54e-03198725869_DN
DrugTroleandomycin [2751-09-9]; Up 200; 5uM; HL60; HG-U133A

BCOR CIR1

1.54e-03198721965_UP
DrugCarbetapentane citrate [23142-01-0]; Down 200; 7.6uM; MCF7; HT_HG-U133A

BCOR CCNT2

1.54e-03198722623_DN
Drugtroglitazone; Down 200; 10uM; MCF7; HT_HG-U133A

BCOR MED1

1.54e-03198726991_DN
DrugEthambutol dihydrochloride [1070-11-7]; Up 200; 14.4uM; HL60; HG-U133A

CIR1 CCNT2

1.54e-03198721981_UP
DrugIsoetharine mesylate salt [7279-75-6]; Down 200; 12uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.55e-03199727170_DN
DrugLobelanidine hydrochloride [6112-86-3]; Up 200; 10.6uM; HL60; HG-U133A

CCNT2 MLLT3

1.55e-03199721747_UP
Drugwortmannin; Down 200; 0.01uM; HL60; HG-U133A

CCNT2 MED1

1.55e-0319972389_DN
DrugClonidine hydrochloride [4205-91-8]; Down 200; 15uM; MCF7; HT_HG-U133A

CIR1 MLLT3

1.55e-03199726814_DN
DrugRiboflavine [83-88-5]; Down 200; 10.6uM; MCF7; HT_HG-U133A

MLLT3 MED1

1.55e-03199726822_DN
Drug2-propylpentanoic acid; Down 200; 50uM; MCF7; HT_HG-U133A

BCOR CIR1

1.55e-03199726982_DN
Drugestradiol, USP; Down 200; 0.01uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.55e-03199727000_DN
DrugKetotifen fumarate [34580-14-8]; Up 200; 9.4uM; PC3; HT_HG-U133A

CCNT2 MLLT3

1.55e-03199725842_UP
Drugchlorpromazine hydrochloride; Down 200; 1uM; MCF7; HT_HG-U133A

BCOR CIR1

1.55e-03199726936_DN
DrugCytisine (-) [485-35-8]; Up 200; 21uM; MCF7; HT_HG-U133A

CIR1 CCNT2

1.55e-03199726217_UP
DrugDiprophylline [479-18-5]; Up 200; 15.8uM; PC3; HT_HG-U133A

BCOR CCNT2

1.55e-03199721811_UP
DrugCyclopentolate hydrochloride [5870-29-1]; Down 200; 12.2uM; HL60; HT_HG-U133A

CCNT2 MLLT3

1.55e-03199726132_DN
DrugPepstatin A [26305-03-3]; Up 200; 5.8uM; PC3; HT_HG-U133A

CCNT2 MLLT3

1.55e-03199724206_UP
DrugDicyclomine hydrochloride [67-92-5]; Down 200; 11.6uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.55e-03199721483_DN
DrugGentamicine sulfate [1405-41-0]; Down 200; 2.6uM; MCF7; HT_HG-U133A

CIR1 CCNT2

1.55e-03199727237_DN
DrugTiclopidine hydrochloride [53885-35-1]; Down 200; 13.4uM; MCF7; HT_HG-U133A

CCNT2 MED1

1.55e-03199721475_DN
DrugOrphenadrine hydrochloride [341-69-5]; Down 200; 13uM; PC3; HT_HG-U133A

CIR1 CCNT2

1.55e-03199724537_DN
DrugFuraltadone hydrochloride [3759-92-0]; Down 200; 11uM; PC3; HT_HG-U133A

CCNT2 MLLT3

1.55e-03199724313_DN
DrugIopamidol [60166-93-0]; Down 200; 5.2uM; HL60; HT_HG-U133A

MLLT3 MED1

1.55e-03199722732_DN
DrugAllantoin [97-59-6]; Down 200; 25.2uM; MCF7; HT_HG-U133A

BCOR CIR1

1.57e-03200725471_DN
DrugIpratropium bromide [22254-24-6]; Down 200; 9.8uM; PC3; HT_HG-U133A

BCOR CIR1

1.57e-03200725823_DN
DrugICI 182,780; Up 200; 0.01uM; PC3; HT_HG-U133A

CIR1 CCNT2

1.57e-03200721238_UP
DrugIsoetharine mesylate salt [7279-75-6]; Up 200; 12uM; MCF7; HT_HG-U133A

CCNT2 MLLT3

1.57e-03200727170_UP
Drug(R)-(+)-Atenolol [56715-13-0]; Down 200; 15uM; MCF7; HT_HG-U133A

CIR1 MLLT3

1.57e-03200724841_DN
DrugGliclazide [21187-98-4]; Down 200; 12.4uM; HL60; HG-U133A

BCOR CCNT2

1.57e-03200721720_DN
Diseaseasthma

MLLT3 MED1

1.25e-0275172MONDO_0004979

Protein segments in the cluster

PeptideGeneStartEntry
HSKMSKSSKSSGSSS

CCNT2

631

O60583
SSSSSTSFSKPHKLM

MLLT3

186

P42568
AKHSSSTSSKGAKAS

BCOR

606

Q6W2J9
SSTTTASTKKMLSSK

ITIH6

671

Q6UXX5
SSASTSGKMKSSKSE

MED1

1106

Q15648
SGKMKSSKSEGSSSS

MED1

1111

Q15648
KSMSTLDKTSTSSHK

MUCL3

191

Q3MIW9
KHKKHKSSSSSSSSS

CIR1

251

Q86X95